Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting
PR Newswire•02/11/2026•08:00 ET
0
Key Highlights
- ➤Nuvation Bio (NUVB) will present updated Phase 2 J201 efficacy and safety results November 13.
- ➤Three posters outline ongoing safusidenib studies, including pivotal Phase 3 SIGMA.
- ➤Phase 3 SIGMA will enroll approximately 300 patients with high-risk IDH1-mutant astrocytoma.
- ➤Safusidenib received FDA Fast Track Designation for IDH1-mutant glioma in August 2026.
Expert Statements
David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio
“Patients with IDH1-mutant glioma are often diagnosed in their 30s and 40s and may live with their disease for many years, underscoring the importance of targeted treatments that can deliver durable responses with a consistent safety profile.”
David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio
“We look forward to sharing updated Phase 2 results that speak to that need, as well as progress across our expanded safusidenib development program, with the clinicians and patient community working to advance care for people living with IDH1-mutant glioma.”
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting PR Newswire
Nuvation Bio will present four posters: one will showcase updated long-term Phase 2 results; three posters highlight trial in progress overviews for ongoing safusidenib studies
Get started
Create a free account to read the full story.